

Commercial Bulletin

Special points of interest:

This bulletin is free to interested people in Pharma & Healthcare

Please send names of new subscribers to
Jackie@wavedata.co.uk

If you have articles, comments or story ideas, please send them to the email above

www.wavedata.co.uk

Millions of Doses of Ebola Vaccine to be produced in 2015

The development and consumption of drugs that could have a major impact on the Ebola disease will be managed by the World Health Organization (WHO).

Pharma companies have committed to ramp up the development and production of vaccines.

The vaccines could potentially bring to an end the epidemic that has claimed nearly 5,000 lives.

Testing of the vaccines is already underway in the United States.

To read more

<http://www.telesurtv.net/english/news/Pharmaceutical-Companies-to-Produce-Millions-of-Doses-of-Ebola-Vaccine-in-2015-20141025-0010.html>

Inside this issue

Millions of Doses of Ebola Vaccine to be produced in 2015

Pain relief for children with fractures

GPs could get a share in £100m

Does supply chain activity predict script volume?

Development of a tablet by Google to detect cancer

3D printer for personalized medicine

Forthcoming events

PRICE WATCH UK - Memantine prices take another tumble

WaveData — Top ten searched products where the focus was to October 2014

Pain relief for children with fractures

According to a study, children that have suffered some kind of bone fracture, Ibuprofen is a better option for pain relief rather than morphine

Fractures account for up to a quarter of all injuries among children, with the most severe pain occurring in the first 48 hours after injury.

Both Morphine and Ibuprofen are both effective in reducing pain, but there may be more side effects with children taking morphine.

The side effects can include nausea, drowsiness and vomiting

To read more

<http://www.medicalnewstoday.com/articles/284474.php>

GPs could get a share in £100m

A £100m cash pot has been provided by the government to see how GPs could improve and extend their working hours.

GPs will have to bid for a cut in the £100m; they will also have to serve a minimum of 30,000 patients.

Practices that open for longer hours, such as 8am to 8pm and weekends, will be given priority.

GPs and primary care do already play an even stronger role in the heart of local communities.

To read more

<http://commissioningsuccess.com/2014/10/gps-invited-to-bid-for-share-of-100m-access-fund/>

Does supply chain activity predict script volume?


Each month wholesalers send price lists to chemists and dispensing doctors. Normally these come through with the same products listed in them each month. However products sometimes appear or disappear, or are added to additional special offers.

Wavedata believe the number of times a product appears in commercial offers each month to reflect the wholesaler's stock availability, but have never had access to sufficient prescription data to see if there is a relationship with prescription volumes.


In 2012 the English government started releasing prescription data by GP surgery at product strength level. Wavedata now have 22 months of historical prescription data in their scriptmap.co.uk service and can begin to investigate this further.

Therefore three commonly prescribed products were investigated; a generic, a brand and a surgical product.

The generic product investigated was Amlodipine Tabs 5mg which was very commonly used with over 40 million tablets prescribed each month. The two trend lines for supply chain activity and prescription volume closely followed the same trend throughout the 22 month period.




Similarly in the case of Lyrica Caps 75mg there appears to be a relationship between the two trends, and sometimes the peaks and troughs happen in the same months and the lines appear to shadow each other.



However the surgical product investigated - Coloplast SpeediCath Male Size 10-14 (30-Pack) Catheter – breaks the rule with the activity dropping dramatically but the script volume flattening out .

Why the number of entries for this catheter declined in price lists is not known and a shortage is suspected. However the PSNC no longer keep a shortages list, but looking into Wavedata’s pricing data showed that only OTC Direct were making the vast majority of sales offers for this catheter during the period November 2013 to July 2014 with Sigma and B & S having stock in some months.



So the outcome of this analysis is that some product’s script volumes do appear to follow the same trend as price list inclusion activity. However other products may not exhibit the same relationship where there is an availability issue or some other factor in play.

Whilst the price list activity is collected in real time, prescription data can take three months to become available. Therefore there is the potential for the development of an early warning system, but that other factors such as shortages can damage the link between the two factors.

Charles Joynson

Wavedata

www.wavedata.net

Development of a tablet by Google to detect cancer

Google is developing a pill that could detect life-threatening illnesses such as cancer and heart disease in the earliest stages.

The tablet is still very much in experimental phase at the Google X lab.

The tablet will contain microscopic particles - nanoparticles - which can travel through the bloodstream and search for early signs of disease.

The data would then be collected by a wrist-worn smart device.

To read more

<http://www.dailymail.co.uk/sciencetech/article-2811523/Google-goes-cancer-Search-giant-s-secretive-X-Lab-reveals-developing-nanoparticles-sniff-disease-early-stages.html>

3D printer for personalized medicine

The move forward for a medical 3D printer will make individualized medicine more affordable.

The machine will be able to produce customized medicines on demand.

One of the main advantage's of the 3D printer is that it could potentially tailor-make drugs specific to a patient's needs.

To read more

<http://www.medicalnewstoday.com/articles/284381.php>

Forthcoming events

Organizer	Date	Venue	Link or Email
EMIG Conference 'How is Specialised Commissioning Developing in the NHS?'	25th November 2014	London	www.emig.org.uk
AMRC masterclass: Developing partnerships with industry	8th December 2014	London	https://www.eventbrite.co.uk/e/developing-partnerships-with-industry-registration-12397022829?ref=ebapi
NHS England – SBRI Healthcare Innovation Expo	10th December 2014	London	http://www.sbrihealthcare.co.uk/
NICE's new scientific advice service for SMEs	18 December 2014	London	https://medicinesevents.nice.org.uk/18dec2014
8th EGA Pharmacovigilance Discussion Forum	21st January 2015	London	www.egaevents.org
14th EGA Regulatory and Scientific Affairs Conference	22-23 January 2015	London	www.egagenerics.com
Free Findacure Workshop on Drug Repositioning	27th February 2014	London	flora@findacure.org.uk

PRICE WATCH UK

Memantine prices take another tumble

Memantine prices took another tumble in October, with the average price of 28-tablet packs of memantine 10mg dropping by more than a fifth (see Figure 1). The lowest price available fell less quickly by 13%, indicating that more than one supplier was discounting. Prices for bulkier supplies of the same product declined even faster, with the average price for 56-tablet packs sinking by nearly a third to £8.02 (US\$12.85). Prices for 28-tablet packs of memantine 10mg sank by nearly a fifth in September (Generics bulletin, 3 October 2014, page 23).

To see more go to <http://www.wavedata.co.uk/newinfo.asp> and view our article from this month's Generics Bulletin.

WaveData

Subscribe to the industry's comprehensive source of news and analysis.

www.generics-bulletin.com



WaveData — Top ten searched products where the focus was to October 2014

According to WaveData, these were the most commonly investigated products in searches of the online pricing data Wavedata
Live at <http://www.wavedata.net>

Both uk and pi prices were viewed for each product, giving some indication of where the focus was to October 2014

Product	Aug-14	Sep-14	Oct-14
Gabapentin Caps 300mg 100	£3.66	£3.48	£3.80
Alendronate Tabs 70mg 4	£0.61	£0.50	£0.48
Co-Codamol Tabs 30mg/500mg 100	£3.83	£3.80	£3.81
Lymecycline Caps 408mg 28	£5.44	£5.69	£6.59
Exemestane Tabs 25mg 30	£9.03	£10.91	£11.71
Omeprazole Caps 20mg 28	£0.60	£0.58	£0.59
Seretide Accuhaler 250mcg 1 (60 Doses)	£33.13	£31.94	£31.47
Temazepam Tabs 10mg 28	£17.17	£16.62	£16.10
Atovaquone + Proguanil Tabs 250mg/100mg 12	£12.73	£13.72	£13.46
Lyrica Caps 75mg 56	£58.33	£57.79	£57.22

This bulletin now goes out to 3900 plus people.

If you would like to add or suggest any articles/comments, please let me know by the 10th December 2014, as I will be issuing the next one on the 17th December 2014

If you have any colleagues who would like to receive this, please let them know about it.

You can view all copies of the Bulletin at
<http://www.wavedata.co.uk/newinfo.asp>

Jackie Moss
WaveData Ltd

E-mail: Jackie@wavedata.co.uk
Twitter [@wavedata](https://twitter.com/wavedata)